InsidersTradesSigma
Follow the Ashland Global Holdings INC stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Chemicals & Materials sector, Ashland Global Holdings INC has logged 31 reports. Market capitalisation: €3.3bn. The latest transaction was disclosed on 9 June 2022 (Levée d'options). Among the most active insiders: WILLIS J KEVIN. All data is free.
31
Insider Decl.
n/a
Thresholds
€5m
1 ops.
Buy Volume
€88,033
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ashland Global Holdings INC Buy (bullish), based on 11 analysts. Average price target: US$77.09.
26Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,864 of 29,065 companies
26.3
score / 100
Value24
Quality29
FCF yld-0.1%
Earn yld-25%
EV/EBITDA·
ROE4.0%
Gross mgn30%
Net mgn-46%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 June 2022
Declarations31 total
5,838 shares@ US$37.3731.5% of flowCommon StockSEC:0001127602-22-017121:0
4,940 shares@ US$46.6529.6% of flowCommon StockSEC:0001127602-22-016626:0
48,800 shares@ US$101.27100.0% of flowCommon Stock, par value $0.01 per share ("Common Stock")SEC:0000902664-22-003033:0
Canonical exit: 15 Aug 2022 (T+90)
2,000 shares@ US$67.1666.0% of flowCommon StockSEC:0001127602-22-012087:0
4,686 shares@ US$94.4359.2% of flowCommon StockSEC:0001127602-22-010159:0
269.391 sharesCommon StockSEC:0001127602-22-003300:0
469 shares0Common StockSEC:0001127602-22-000460:0
26 shares@ US$104.010.1% of flowCommon StockSEC:0001127602-21-031632:0
8,996 shares@ US$104.0141.2% of flowCommon StockSEC:0001127602-21-031072:0
1,130 shares@ US$37.37100.0% of flowCommon StockSEC:0001127602-21-030222:0
1,393 shares@ US$108.170.0046% mcap6.6% of flowCommon StockSEC:0000950157-21-001210:0
2,524 shares@ US$106.930.0084% mcap12.0% of flowCommon StockSEC:0000950157-21-001211:0
7,858 shares@ US$106.9336.8% of flowCommon StockSEC:0001127602-21-029727:0
319 shares@ US$106.934.7% of flowCommon StockSEC:0001127602-21-029719:0
571 shares@ US$106.9328.7% of flowCommon StockSEC:0001127602-21-029729:0
1,396 shares@ US$106.9319.5% of flowCommon StockSEC:0001127602-21-029726:0
571 shares@ US$106.9374.3% of flowCommon StockSEC:0001127602-21-029722:0
2,524 shares@ US$106.9332.6% of flowCommon StockSEC:0001127602-21-029728:0
621.995 shares@ US$106.93100.0% of flowCommon StockSEC:0001127602-21-029730:0
4,675 shares@ US$108.1721.9% of flowCommon StockSEC:0001127602-21-029467:0
841 shares@ US$108.1711.8% of flowCommon StockSEC:0001127602-21-029465:0
1,393 shares@ US$108.1718.0% of flowCommon StockSEC:0001127602-21-029471:0
172 shares@ US$108.172.5% of flowCommon StockSEC:0001127602-21-029463:0
25 of 31 declarations
关于 Ashland Global Holdings INC
Ashland Global Holdings Inc. (NYSE: ASH) 是一家在美国纽约证券交易所上市的公司，专注于特种添加剂和成分。Ashland 总部位于特拉华州威尔明顿，拥有一个多世纪的悠久工业历史，并已逐步将其投资组合转型为更专注、更高价值的业务，以高性能成分和配方科学为核心。该公司主要服务于生命科学、个人护理和建筑涂料等终端市场，在这些市场中，技术差异化、产品质量和客户支持比商品定价更为重要。（[investor.ashland.com](https://investor.ashland.com/corporate-profile?utm_source=openai)） 如今，Ashland 作为功能性添加剂和特种成分的全球供应商运营。其业务涵盖药用辅料和赋形材料、个人护理成分以及用于涂料和其他工业配方的添加剂。在个人护理领域，该公司强调用于皮肤、头发、口腔护理、微生物防护和家庭护理的生物功能活性物质和成分。在特种添加剂方面，Ashland 提供旨在提高增稠效率、流平性、抗流挂性、基材润湿性、滑爽性和整体配方性能的技术。安全性、法规遵从性和产品质量是该公司定位中反复出现的主题，因为它们在其所服务的严格监管市场中至关重要。（[investor.ashland.com](https://investor.ashland.com/news-releases/news-release-details/ashland-announces-strategic-partnership-imcd-exclusive?utm_source=openai)） 从竞争角度来看，Ashland 最好被视为一个拥有强大技术专长的利基特种化学品公司，而非一家大宗材料公司。其优势来自于应用专业知识、专有平台、与配方师的密切关系以及全球市场推广模式。管理层继续将 Ashland 描述为制药、个人护理和建筑涂料等高质量、面向消费者的市场中的领导者。这种定位赋予该公司在特定领域有吸引力的定价权，尽管这也使其在宏观经济状况疲软时，在某些涂料、建筑和工业渠道中面临需求疲软的风险。（[investor.ashland.com](https://investor.ashland.com/news-releases/news-release-details/ashland-reports-first-quarter-fiscal-2026-results-and-narrows?utm_source=openai)） 在地理上，Ashland 通过全球范围内的商业、技术和制造能力为全球客户提供服务。最近的更新也显示了明确的投资组合优化议程。该公司一直在削减非核心或利润较低的业务，同时再投资于创新驱动的增长平台。2025 年和 2026 年，Ashland 推出了 collapeptyl™，这是一种用于胶原蛋白相关护肤应用的新型生物功能活性物质，完成了 Avoca 业务的出售，并宣布与 IMCD 建立独家美国分销合作伙伴关系，负责其个人护理和家庭护理成分。这些行动强调了专注于简化、改善产品组合和增强客户覆盖范围的战略。（[investor.ashland.com](https://investor.ashland.com/news-releases/news-release-details/ashland-unveils-collapeptyltm-revolutionary-biofunctional?utm_source=openai)） 对于投资者而言，Ashland 作为一家拥有悠久经营历史、精炼投资组合并涉足有吸引力终端市场的特种化学品公司而脱颖而出。其最近的公司行动表明，该公司将继续强调创新、成本控制和利润改善，而其在美国纽约证券交易所的上市地位使其对跟踪特种材料名称的美国和国际股票投资者都具有相关性。（[investor.ashland.com](https://investor.ashland.com/news-releases/news-release-details/ashland-reports-first-quarter-fiscal-2026-results-and-narrows?utm_source=openai)）
